Catalyst

Slingshot members are tracking this event:

Regeneron (REGN) and Sanofi's (SNY) Biologics License Application for Dupilumab in Atopic Dermatitis (AD) Accepted for Priority Review by FDA

Source Link:
http://files.shareholder.com/downloads/REGN/2835364741x0x909424/1D85408D-E261-491A-8B0B-EFE11EC65098/REGN_News_2016_9_26_General_Releases.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
REGN
100%
SNY
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 26, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Bla, Biologics License Application, Dupilumab, Atopic Dermatitis, Priority Review, Fda
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.